Biotech industry faced challenges in 2024, but young firms hold potential; Avadel Pharmaceuticals a buy.
From Investing.com: 2025-01-21 11:53:00 Despite economic strength, the biotech industry faced challenges in 2024. The iShares Biotechnology ETF ended down
